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 Measurement of glomerular  ltration rate 
(GFR) is the most widely accepted stand-
ard for the assessment of renal function in 
health and disease. Classical clearance 
methods, involving a constant infusion of 
a glomerular  ltration marker such as inu-
lin, are too cumbersome for routine clini-
cal use. However, these methods are o$ en 
used when a precise measurement of GFR 
is essential, such as in research studies or 
in the evaluation of living donors, in 
whom a normal level of GFR is a neces-
sary quali cation. Adaptations of classical 
clearance methods, such as the subcutane-
ous administration of  125 I-labeled iotha-
lamate, have been proven to correlate 
highly with inulin clearance methods, but 
they require specialized equipment, a 
license to use radioisotopes, and several 
urine-collection periods. 1 Measurement 
of endogenous creatinine clearance (Ccr) 
by 24-h urine sampling, as an approxima-
tion for GFR, has been used for many dec-
ades, but di.  culties in assuring complete 
and accurate urinary collections have 
raised questions regarding its reliability in 
 routine clinical  circumstances. 
 Not surprisingly, even simpler approaches 
that estimate renal function from single 
measurements of the level of creatinine in 
serum have appeared, but not without sac-
ri cing accuracy relative to true GFR. Jelli1 e 
in 1973 2 and Cockcro$  and Gault in 1976 3 
were among the  rst to advocate a predic-
tion of measured Ccr based on serum cre-
atinine measurements alone. Their 
prediction formulae use age, body weight, 
and sex as surrogates for endogenous cre-
atinine generation and excretion and are 
simple to use. However, Ccr is not equivalent 
to GFR, because of the effect of tubular 
secretion of creatinine. In normal subjects, 
Ccr (measured or calculated) overestimates 
true GFR by about 20 – 25 % . In 1999, Levey 
and co-workers 4 introduced the estimation 
of GFR (eGFR) by a new formula derived 
from an analysis of subjects participating in 
the Modi cation of Diet in Renal Disease 
(MDRD) Study, all of whom had established 
chronic kidney disease (CKD). ? is equa-
tion (eGFR-MDRD) is now used through-
out the world as a simple method of 
indirectly assessing GFR. In order to improve 
accuracy, this formula is best applied to situ-
ations in which the creatinine assays are 
calibrated to a uniform standard (a slightly 
modi ed re-expression of the original eGFR-
MDRD equation is recommended when 
such standardized assays are used 5 ). Addi-
tional formulae, such as CKD-EPI 6 and the 
Mayo Clinic 7 quadratic  equations, have also 
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 Measurement of the glomerular filtration rate (GFR) is an essential 
element in assessing renal function. Formulaic estimations of GFR 
(eGFRs) are widely used but have many pitfalls. Application of eGFR 
without adjustment for the effects of aging and gender results in 
overdiagnosis of chronic kidney disease (CKD). eGFR formulae also 
contain variables that independently influence the risk of CKD and 
cardiovascular disease. eGFR needs a performance review to foster its 
evolution as a clinically useful tool. 
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been proposed to overcome, at least in part, 
some of the bias and imprecision that have 
plagued the eGFR-MDRD equation. ? ese 
and all other methods for assessments of 
GFR require that the subject be in a  ‘ steady 
state. ’ Estimations of renal function by eGFR-
MDRD are also used for diagnostic and epi-
demiologic purposes to de ne the presence 
of CKD, by incorporation of the calculated 
value for eGFR-MDRD into the Kidney Dis-
ease Outcomes Quality Initiative (KDOQI) 8 
schema for classi cation of CKD, later also 
adopted by Kidney Disease: Improving Glo-
bal Outcomes (KDIGO). 9 ? ese classi ca-
tion schemata allow for the diagnosis of 
CKD whenever the eGFR is less than 60  ml /
 min per 1.73  m 2 and is sustained for 3 
months or longer, even in the absence any 
corroborating evidence of kidney damage 
(such as proteinuria, abnormal imaging, or 
renal pathology). Routine reporting of eGFR 
each time serum creatinine is measured is 
now advocated in many countries and by 
many professional organizations. Very 
clearly, such an approach constitutes  de facto 
screening for CKD. 10 
 Compared with true GFR measured by 
research-grade clearance methods, the 
eGFR-MDRD estimating formulae (origi-
nal and re-expressed versions) su1 er from 
both bias (systematic underestimation of 
true GFR) and imprecision (wide coe.  -
cient of variation), particularly at higher 
levels of GFR. 11 ? e new CKD-EPI equa-
tion appears to reduce some of the bias and 
imprecision found with the eGFR-MDRD 
equation, particularly at higher levels of 
GFR (>60  ml / min per 1.73  m 2 ). 6 Estima-
tion of GFR by formulae incorporating 
serum creatinine also requires unique 
adjustments depending on the ancestry of 
the population under study, 12 and their 
validity in diverse circumstances, such as 
marked obesity, malnutrition, and strict 
vegetarianism, has not been satisfactorily 
explored or tested. Epidemiologic studies 
using the combination of the eGFR-MDRD 
and the KDOQI / KDIGO constructs for 
defining CKD have led to estimates of 
12 – 13 % for the global prevalence of CKD 
in the community at large. 13 Observational 
studies have also suggested that a reduced 
( <  60  ml / min per 1.73  m 2 ) or declining 
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is now very evident. GFR-estimating equa-
tions are best applied when the diagnosis 
of CKD is already quite evident from other 
studies, such as persistent proteinuria, 
abnormal imaging, or pathology. 7 
 The second article, by Rule and co-
workers 17 (this issue), provides some 
novel and fresh insights into the assess-
ment of risk for both CKD and CVD that 
rely on formulaic estimates of Ccr (and, 
by inference, eGFR-MDRD) that utilize 
surrogates such as age and sex for endog-
enous creatinine generation. Observa-
tional studies have shown an association 
between both a reduced and a declining 
eGFR-MDRD (and thereby endogenous 
Ccr), and enhanced CVD risk. 14,15 ? is 
association is steeper and more robust 
when the eGFR is less than 45  ml / min per 
1.73  m 2 and is greatly magni ed by the 
concomitant presence of proteinuria. 
Indeed, the PREVEND study 21 demon-
strated that individuals with an eGFR less 
than 60  ml / min per 1.73  m 2 without con-
comitant abnormal proteinuria are not at 
increased risk of CVD compared with 
those with an eGFR greater than 60  ml /
 min per 1.73  m 2 . ? e study of Rule  et al . 17 
clearly shows that these surrogates (age 
and sex) also predict outcomes quite 
independently of their correlation with 
estimated or measured Ccr. Estimating 
equations based on directly assessed mus-
cle mass (the principal source of endog-
enous creatinine generation) reduce the 
strength of the association of reduced 
renal function and enhanced risk of CVD. 
Equations for estimation of renal function 
from serum creatinine values that include 
age and sex as surrogates for endogenous 
creatinine generation also greatly increase 
the prevalence of CKD as compared with 
equations that include muscle mass alone. 
One may conclude that the parameters 
included in GFR- or Ccr-estimating equa-
tions, such as age and sex, exert their 
inL uence twice — they act as surrogates 
for creatinine generation, and they also 
independently inL uence the magnitude 
of the association of the derived result of 
estimated renal function with outcomes 
such as CKD and CVD. Thus, the 
 estimating equations that include age and 
sex as variables (such as eGFR-MDRD 
and Cockcro$  – Gault Ccr) may inL ate 
even further the apparent risk of CKD in 
eGFR is associated with an enhanced risk 
for cardiovascular disease (CVD) and mor-
tality, 14,15 although the precise causal 
mechanisms underlying this association 
are unexplained. However, despite all of its 
shortcomings, the eGFR concept has 
become  rmly embedded into the com-
mon lexicon of nephrology. Advocates of 
the eGFR construct propose that its meas-
urement has many potential applications, 
particularly when it is used in the context 
of the KDOQI / KDIGO classi cation sche-
mata for CKD. Some of the proposed 
potential clinical applications of eGFR are 
shown in Figure 1. As is discussed in this 
Commentary, the true value of many of 
these potential applications requires a care-
ful reappraisal of their performance, espe-
cially in real-life situations. 
 Two articles appearing in this issue of 
 Kidney International 16,17 serve as examples 
of the need for a performance review of 
the eGFR concept in relation to the diag-
nosis of and screening for CKD (as pres-
ently defined), for the qualification of 
living donors for transplantation, and in 
its application as a risk factor for CVD. 
? e  rst of these articles, by Poggio  et al ., 16 
addresses the evaluation of renal function 
in a very large cadre / cohort ( N  =  1592) of 
healthy (by de nition) living donors for 
renal transplantation. As expected, eGFR-
MDRD consistently underestimated 
measured GFR ( 125 I-iothalamate clear-
ance), by about 16 % overall. Importantly, 
eGFR declined with age, more rapidly 
after age 45 years, such that the mean 
eGFR was 80 and 78  ml / min per 1.73  m 2 
in males and females, respectively, at age 
60 years (there were very few donors over 
age 65 years), and the 5th percentile for 
eGFR fell below 60  ml / min per 1.73  m 2 at 
age 55 years and above for males and at 
age 50 and above for females. None of 
these individuals had diabetes, hyperten-
sion, known CVD, or abnormal proteinu-
ria. More than one-quarter of these healthy 
subjects would have been excluded from 
donation if a criterion of an eGFR greater 
than 80  ml / min per 1.73  m 2 had been rig-
idly applied. Other cross-sectional studies 
have also emphasized the broad range of 
values for eGFR-MDRD that vary by age 
and sex in otherwise  ‘ healthy ’ adults in the 
community at large . For example, in the 
Nijmegen Biomedical Study, the  ‘ normal ’ 
range (5th to 95th percentile) of eGFR-
MDRD in males was about 80 – 140  ml / min 
per 1.73  m 2 at age 25 years and declined to 
about 40 – 100  ml / min per 1.73  m 2 at age 
80 – 85 years. 18 Slightly lower values are 
found in females of comparable ages. 
? ese studies amplify previous concerns 
that a single cuto1  value for GFR, regard-
less of age or sex, in order to qualify as a 
living donor may not be appropriate. 19 
Even more importantly, they collectively 
re-emphasize that a single  ‘ absolute ’ eGFR-
based criterion, unadjusted for the normal 
decline in GFR with aging and by sex, will 
inevitably lead to a frequent  ‘ false positive ’ 
diagnosis of CKD (mostly at the stage 3 
level), particularly in elderly women, and 
also to an overstatement of the prevalence 
of CKD whenever the KDOQI criteria are 
used for diagnosis (or screening). 20 ? is 
weakness in the performance of the 
eGFR – KDOQI / KDIGO – CKD constructs 
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 Figure 1 |  The potential applications of estimated GFR (eGFR) in clinical medicine. Red, not 
realized; green, realized; yellow, partially realized or uncertain. CKD, chronic kidney disease. 
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the elderly and in women, as well as the 
risks for CVD associated with a reduced 
estimated level of renal function. ? ese 
 ndings have broad importance to the 
understanding of the epidemiology of 
CKD and its consequences and add fur-
ther to the urgency of a re-evaluation of 
the performance of eGFR. ? ey generate 
questions regarding the utility of renal 
function–estimating equations based on 
serum creatinine, such as eGFR-MDRD, 
for the assessment of renal function in 
clinical medicine. Clearly, these formulae 
and their application to epidemiology 
have helped to heighten awareness of 
CKD and its complications, but to move 
forward, new approaches are needed (i) 
that obviate the use of surrogates for cre-
atinine generation; (ii) that take account 
of the e1 ect of age and gender on GFR; 
and (iii) that use markers for GFR other 
than creatinine. Perhaps cystatin C or a 
combination of cystatin C and creatinine 
will ultimately ful ll this latter role. 22 ? e 
eGFR-MDRD and other estimates of 
renal function based on serum creatinine 
alone require an objective performance 
review of their roles in clinical medicine. 
GFR estimation must evolve into a more 
precise and accurate art. 
 DISCLOSURE 
 The author declared no competing interests. 
 ACKNOWLEDGMENTS 
 Christopher Winearls (Oxford University) 
provided invaluable advice in the preparation 
of this Commentary. 
 REFERENCES 
 1 .  Israelit  AH ,  Long  DI ,  White  MG  et al.  Measurement 
of glomerular filtration rate utilizing a single 
subcutaneous injection of  125 I-iothalamate .  Kidney 
Int  1973 ;  4 :  346 – 350 . 
 2 .  Jelliffe  RW .  Creatinine clearance: bedside estimate . 
 Ann Intern Med  1973 ;  79 :  604 – 605 . 
 3 .  Cockcroft  DW ,  Gault  MH .  Prediction of creatinine 
clearance from serum creatinine .  Nephron  1976 ; 
 16 :  31 – 41 . 
 4 .  Levey  AS ,  Bosch  JP ,  Lewis  JB  et al.  A more 
accurate method to estimate glomerular 
filtration rate from serum creatinine: a new 
prediction equation. Modification of Diet in Renal 
Disease Study Group .  Ann Intern Med  1999 ;  130 : 
 461 – 470 . 
 5 .  Levey  AS ,  Coresh  J ,  Greene  T  et al.  Expressing 
the Modification of Diet in Renal Disease Study 
equation for estimating glomerular filtration rate 
with standardized serum creatinine values .  Clin 
Chem  2007 ;  53 :  766 – 772 . 
 6 .  Levey  AS ,  Stevens  LA ,  Schmid  CH  et al.  A new 
equation to estimate GFR from serum creatinine: 
improved accuracy and updated estimates 
of prevalence of chronic kidney disease in 
the United States .  J Am Soc Nephrol  2008 ;  19 :  
 36A  (abstr.) . 
 7 .  Rule  AD .  Understanding estimated glomerular 
filtration rate: implications for identifying chronic 
kidney disease .  Curr Opin Nephrol Hypertens  2007 ; 
 16 :  242 – 249 . 
 8 .  National Kidney Foundation .  Clinical Practice 
Guidelines for Chronic Kidney Disease: Evaluation, 
Classification and Stratification .  Am J Kidney Dis 
 2002 ;  39 (Suppl 1) :  s19 . 
 9 .  Levey  AS ,  Eckardt  K-U ,  Tsukamoto  Y  et al.  Definition 
and classification of chronic kidney disease: 
a position statement from Kidney Disease: 
Improving Global Outcomes (KDIGO) .  Kidney Int 
 2005 ;  67 :  2089 – 2100 . 
 10 .  Glassock  EJ ,  Winearls  CG .  Routine reporting of 
estimated glomerular filtration rate: not ready 
for prime time .  Nat Clin Pract Nephrol  2008 ;  4 : 
 422 – 423 . 
 11 .  Froissart  M ,  Rossert  J ,  Jacquot  C  et al.  Predictive 
performance of the Modification of Diet in Renal 
Disease and Cockcroft-Gault equations for 
estimating renal function .  J Am Soc Nephrol  2005 ; 
 16 :  763 – 773 . 
 12 .  Ma  YC ,  Zuo  L ,  Chen  JH  et al.  Modified glomerular 
filtration rate estimating equation for Chinese 
patients with chronic kidney disease .  J Am Soc 
Nephrol  2006 ;  17 :  2937 – 2944 . 
 13 .  Glassock  RJ ,  Winearls  CG .  The global burden 
of chronic kidney disease: how valid are the 
estimates?  Nephron Clin Pract  2008 ;  110 :  c39 – c46 . 
 14 .  Tonelli  M ,  Pfeffer  M .  Kidney disease and 
cardiovascular risk .  Annu Rev Med  2007 ;  58 :  123 – 139 . 
 15 .  Rifkin  DE ,  Shlipak  MG ,  Katz  R  et al.  Rapid kidney 
function decline and mortality risk 
in older adults .  Arch Intern Med  2008 ;  168 : 
 2212 – 2218 . 
 16 .  Poggio  ED ,  Rule  AD ,  Tanchanco  R  et al. 
 Demographic and clinical characteristics 
associated with glomerular filtration rates 
in living kidney donors .  Kidney Int  2009 ;  75 :  
 1079 – 1087 . 
 17 .  Rule  AD ,  Bailey  KR ,  Schwartz  GL  et al.  For 
estimating creatinine clearance measuring 
muscle mass gives better results than those 
based on demographics .  Kidney Int  2009 ;  75 : 
 1071 – 1078 . 
 18 .  Wetzels  JF ,  Klemeney  LA ,  Swinkels  DW  et al.  Age- 
and gender-specific reference values of estimated 
GFR in Caucasians: the Nijmegen Biomedical 
Study .  Kidney Int  2007 ;  72 :  632 – 637 . 
 19 .  Gonwa  TA ,  Atkins  C ,  Zhang  YA  et al.  Glomerular 
filtration rates in persons evaluated as living-
related donors: are our standards too high? 
 Transplantation  1992 ;  55 :  983 – 985 . 
 20 .  Glassock  RJ ,  Winearls  CG .  Screening for CKD with 
eGFR: doubts and dangers .  Clin J Am Soc Nephrol 
 2008 ;  3 :  1563 – 1568 . 
 21 .  Brantsma  AH ,  Bakker  SJ ,  Hillege  HL  et al. 
 Cardiovascular and renal outcomes in subjects 
with K/DOQI stage 1 – 3 chronic kidney disease: the 
importance of urinary albumin excretion .  Nephrol 
Dial Transplant  2008 ;  23 :  3851 – 3858 . 
 22 .  Stevens  LA ,  Coresh  J ,  Schmid  CH  et al.  Estimating 
GFR using serum cystatin C alone and in 
combination with serum creatinine: a pooled 
analysis of 3418 individuals with CKD .  Am J Kidney 
Dis  2008 ;  51 :  395 – 406 . 
 The international realities of live 
donor kidney transplantation 
 Francis L.  Delmonico 1 
 Horvat and coauthors report on trends in living kidney transplantation 
in 69 countries, having assembled the data from registries, national 
societies, the medical literature, and direct contact with transplant 
centers. Assembling worldwide data on live-donor kidney transplants is 
a commendable accomplishment that serves the international 
transplant community well. 
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 In this issue of  Kidney International , 
Horvat and coauthors 1 report on trends 
in living kidney transplantation in 69 
countries, having assembled the data 
from registries, national societies, and 
the medical literature. In those countries 
in which there were no registry data, the 
authors contacted the transplant centers 
directly to acquire the data. Assembling 
worldwide data on live-donor kidney 
transplants is a commendable accom-
plishment that serves the international 
